Drug
VA106483
VA106483 is a pharmaceutical drug with 6 clinical trials. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 6 completed trials
Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
1
17%
Ph phase_1
5
83%
Phase Distribution
5
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
5(83.3%)
Phase 2Efficacy & side effects
1(16.7%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
6 of 6 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Completed(6)
Detailed Status
Completed6
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 15 (83.3%)
Phase 21 (16.7%)
Trials by Status
completed6100%
Recent Activity
0 active trials
Showing 5 of 6
completedphase_1
Efficacy and Safety of VA106483 in Elderly Males
NCT00879138
completedphase_1
VA106483 Dose Response Study in Elderly Males
NCT00922740
completedphase_2
Efficacy Study of VA106483 in Males With Nocturia.
NCT01038843
completedphase_1
Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH)
NCT01330927
completedphase_1
VA106483 Dose Response in Females
NCT01171391
Clinical Trials (6)
Showing 6 of 6 trials
NCT00879138Phase 1
Efficacy and Safety of VA106483 in Elderly Males
NCT00922740Phase 1
VA106483 Dose Response Study in Elderly Males
NCT01038843Phase 2
Efficacy Study of VA106483 in Males With Nocturia.
NCT01330927Phase 1
Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH)
NCT01171391Phase 1
VA106483 Dose Response in Females
NCT00879216Phase 1
VA106483 and Alpha Blocker Interaction Study in Elderly Males
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6